It has been suggested that a VEGF inhibitor in combination with chemotherapy could enhance PD-L1 inhibitor-induced T-cell-mediated cancer cell death, by reversing VEGF-induced immunosuppression by promoting the infiltration of T-cells into the tumor microenvironment and enabling T-cell activity against tumor antigens, alongside chemotherapy-induced cancer cell death [13]. Here, VEGFA is linked to neoplasm.